LONG-TERM SAFETY PROFILE OF THE ORAL SPLEEN TYROSINE KINASE INHIBITOR FOSTAMATINIB IN IMMUNE THROMBOCYTOPENIA (ITP) AND OTHER DISEASES
a Department of Haematology, St James’ University Hospital, Leeds, United Kingdom
b Dept. of Clinical Science, Rigel Pharmaceuticals, Inc., South San Francisco, United States
c Medical Affairs, Rigel Pharmaceuticals, Inc., South San Francisco, United States
d Department of Research, Rigel Pharmaceuticals, Inc., South San Francisco, United States
e Medical Affairs Knight Therapeutics, São Paulo, Brazil
Lido
896
Vezesque se leu este artigo
371
Total PDF
525
Total HTML
| Ano/Mês | Html | Total | |
|---|---|---|---|
| 2025 6 | 26 | 15 | 41 |
| 2025 5 | 47 | 14 | 61 |
| 2025 4 | 38 | 13 | 51 |
| 2025 3 | 44 | 14 | 58 |
| 2025 2 | 36 | 18 | 54 |
| 2025 1 | 39 | 20 | 59 |
| 2024 12 | 21 | 11 | 32 |
| 2024 11 | 28 | 18 | 46 |
| 2024 10 | 25 | 13 | 38 |
| 2024 9 | 29 | 16 | 45 |
| 2024 8 | 22 | 15 | 37 |
| 2024 7 | 28 | 27 | 55 |
| 2024 6 | 25 | 20 | 45 |
| 2024 5 | 28 | 29 | 57 |
| 2024 4 | 17 | 10 | 27 |
| 2024 3 | 24 | 29 | 53 |
| 2024 2 | 13 | 19 | 32 |
| 2024 1 | 9 | 9 | 18 |
| 2023 12 | 9 | 23 | 32 |
| 2023 11 | 13 | 29 | 42 |
| 2023 10 | 4 | 9 | 13 |
Mostrar tudo
